Nerisona (Diflucortolone Valerate)

Diflucortolone valerate binds to glucocorticoid receptors inside skin cells. This complex moves to the cell nucleus and alters gene expression, suppressing the production of inflammatory mediators while increasing anti‑inflammatory proteins. The result is reduced leukocyte infiltration, edema and immune activation in the skin.

The specific dose and frequency of Nerisona are determined by the prescribing healthcare professional based on the severity of the skin condition, the area to be treated and patient factors. Patients should follow the exact instructions provided on the prescription label.

Safety data for diflucortolone valerate in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using Nerisona.

To request Nerisona, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Diflucortolone valerate is a high‑potency corticosteroid, offering stronger anti‑inflammatory effects than low‑ to medium‑potency agents such as hydrocortisone. Compared with other high‑potency steroids, its efficacy is similar, but the safety profile and risk of skin atrophy may differ, so selection depends on the clinical scenario and physician judgment.

Nerisona should be stored below 25 °C in its original container, protected from moisture and light. Keep the product out of reach of children and avoid freezing. Do not use the medication after the expiry date printed on the packaging.

Apply a thin layer of Nerisona to the clean, dry skin area affected by the condition, usually once or twice daily as directed by the prescriber. Gently rub the cream or ointment until it disappears, and wash hands after application unless the hands are the treatment site.

Serious risks include skin atrophy (thinning), development of telangiectasia (visible blood vessels), and systemic cortisol suppression when large surface areas are treated for prolonged periods. These effects can lead to increased fragility, bruising or adrenal insufficiency, requiring medical evaluation if they occur.

Nerisona should be avoided in patients with known hypersensitivity to diflucortolone valerate or any excipients, in untreated fungal, bacterial or viral skin infections, and in individuals where a less potent corticosteroid would be sufficient. Children, especially under two years of age, should use it only under strict medical supervision.